Deucravacitinib(BMS-986165) - 半岛电竞官方网址

	Name: BMS-986165 CAS#: 1609392-27-9 Chemical Formula: C20H19D3N8O3 Exact Mass: 425.2003 Molecular Weight: 425.4673
Storage	-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Technical Information	Synonym: BMS 986165; Deucravacitinib; BMS-986165; Sotyktu; BMS986165 Chemical Name: 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide SMILES Code: O=C(C1=NN=C(NC(C2CC2)=O)C=C1NC3=CC=CC(C4=NN(C)C=N4)=C3OC)NC([2H])([2H])[2H]

Name: BMS-986165
CAS#: 1609392-27-9
Chemical Formula: C20H19D3N8O3
Exact Mass: 425.2003
Molecular Weight: 425.4673

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Technical Information

Synonym: BMS 986165; Deucravacitinib; BMS-986165; Sotyktu; BMS986165
Chemical Name: 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide
SMILES Code: O=C(C1=NN=C(NC(C2CC2)=O)C=C1NC3=CC=CC(C4=NN(C)C=N4)=C3OC)NC([2H])([2H])[2H]

Target	Tyk2
In Vitro	Tyk2-IN-4 blocks receptor-mediated Tyk2 activation by stabilizing the regulatory pseudokinase domain of the protein[1].
In Vivo	Lupus-like disease is strongly inhibited in NZB/W mice treated with Tyk2-IN-4. Tyk2-IN-4 is safe and overall well-tolerated. There are no serious adverse events and the frequency of non-serious adverse events are similar in the active (75%) and placebo (76%) groups. After oral administration, Tyk2-IN-4 is rapidly absorbed and exhibits an apparent elimination half-life of 8-15 hours[1].
Solvent	[1]. SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2

Target

Tyk2

In Vitro

Tyk2-IN-4 blocks receptor-mediated Tyk2 activation by stabilizing the regulatory pseudokinase domain of the protein[1].

In Vivo

Lupus-like disease is strongly inhibited in NZB/W mice treated with Tyk2-IN-4. Tyk2-IN-4 is safe and overall well-tolerated. There are no serious adverse events and the frequency of non-serious adverse events are similar in the active (75%) and placebo (76%) groups. After oral administration, Tyk2-IN-4 is rapidly absorbed and exhibits an apparent elimination half-life of 8-15 hours[1].

Solvent

[1]. SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2

CAS NO:	1609392-27-9
规格:	≥98%

包装	价格(元)
2mg	电议
5mg	电议
10mg	电议
25mg	电议
50mg	电议
100mg	电议
250mg	电议